Related Experiment Video
Updated: Jun 3, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
Possible site of action of CGRP antagonists in migraine
Peer Tfelt-Hansen1, Jes Olesen
1University of Copenhagen, Copenhagen, Denmark. ptha@glo.regionh.dk
Background:
The calcitonin gene-related peptide (CGRP) receptor antagonists olcegepant and telcagepant are very potent drugs. Both are effective in migraine but in doses much higher than would be predicted from receptor binding and other in vitro results. This could perhaps suggest an effect of CGRP antagonists behind the blood-brain barrier (BBB), i.e. in the central nervous system (CNS).
Methods:
Comparison of doses needed for CGRP blocking effect in vitro with dose needed in vivo in man and monkeys. Discussion of these doses in relation to doses needed for anti-migraine activity.
Results:
In vivo studies in monkeys and man showed that high doses compared to doses needed in vitro are needed to block capsaicin-induced in skin blood flow, a CGRP-mediated reaction. These doses are close to those needed for anti-migraine activity.
Conclusion:
The apparently high doses of CGRP receptor antagonists, olcegepant and telcagepant needed for anti-migraine effect are not so high after all. They do not allow a conclusion as to whether CGRP antagonists act on peripheral sites or central sites in migraine.
Related Concept Videos
Cholinergic Receptors: Muscarinic
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+. Activation...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
GPCRs Regulate Adenylyl Cylase Activity
Two...

